2017
1
2016-11-03 17:00:00
"Operator: Ladies and gentlemen, thank you for standing by and welcome to the Alnylam Pharmaceuticals conference call to discuss first quarter 2017 financial results. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company.
Christine Lindenboom: Good morning. I am Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, Chief Executive Officer, Barry Greene, President, Akshay Vaishnaw, Executive Vice President of R&D and Mike Mason, Vice President of Finance and Treasurer. In addition, Yvonne Greenstreet, Executive Vice President and Chief Operating Officer is in the room and available for Q&A. For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investor page of our website, www.alnylam.com. During today's call, as outlined in slide two, John will provide some introductory remarks and provide some general context, Akshay will review recent clinical updates, Mike will review our financials and Barry will provide a brief summary of upcoming milestones before opening the call for your questions. Before I begin, I would like to remind you that this call will contain remarks concerning Alnylam's future expectations, plans and prospects which constitute forward-looking statements for the purposes of our Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual report on file with the SEC. In addition, any forward-looking statements represent our views only as of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I would like to turn the call over to John.
John Maraganore: Thanks, Christine, and thank you everyone for joining us this morning. During the first quarter of 2017 and recent period, we made important progress in advancing RNAi therapeutics through clinical trials and towards the market. With 2017 promising to be a key year for company, as we read our results of our Phase 3 study of patisiran and if positive, file our first applications for regulatory approvals, advance three additional programs into Phase 3 trials and prepare to make the anticipated transition to a commercial stage company. We believe these key events put us well on track to meeting our Alnylam 2020 goals of becoming a multiproduct commercial stage company with a deep and sustainable development pipeline by the end of 2020. In my introductory remarks, I would like to provide some further context on these key 2017 events. First, starting with patisiran, an investigational RNAi therapeutic for the treatment of patients with polyneuropathy due to hereditary ATTR amyloidosis. We look forward to reporting topline data from the APOLLO Phase 3 trial in mid-2017, likely in the September timeframe. And assuming positive results, expect to submit an NDA and MAA at year-end. We are encouraged about APOLLO based on the continued promising results from our ongoing Phase 2 open label extension or OLE study of patisiran where we are seeing consistent evidence for potential halting or improvement of neuropathy progression in patients with hATTR. Now, as many of you are aware, we expect that Ionis will very soon report their topline results from their Phase 3 NEURO-TTR study of IONIS-TTRRx, an antisense program in hATTR. While we do expect this study to be generally positive confirming the TTR lowering hypothesis, there is certainly a chance for mixed or even false-negative results based on their smaller sample size, shorter study duration, use of a co-primary endpoint structure that includes quality of life, potentially higher discontinuation rates due to adverse events or other factors and slower less robust TTR lowering effect amongst others. Accordingly, a potentially mixed or negative Ionis study outcome needs to be viewed in the context of their drug and their study, not ours. The second area of major focus for Alnylam in 2017 is the expected advancement of three additional programs into Phase 3, including fitusiran for hemophilia, givosiran for porphyria and with our partners at The Medicines Company, inclisiran for hypercholesterolemia. Strategically, this positions Alnylam to have a steady flow of Phase 3 readouts and if positive commercial launches on potentially an annual basis going forward starting in 2018. With fitusiran, we are completing our alignment with regulators on the ATLAS Phase 3 program and we fully expect to initiate this Phase 3 program by the end of Q2 in line with our guidance. With givosiran, our recent PRIME designation with the EMA has opened the door for discussions on the potential for more accelerated paths for this program in porphyria while our guidance remains with the start of Phase 3 in late 2017. Finally with inclisiran, our partners at The Medicines Company have completed their discussions with FDA confirming an LDL lowering Phase 3 trial as the foundation to support an NDA filing and MedCo has updated their guidance to now report Phase 3 data in 2019. In the coming quarter, we will also be sharing new data for both fitusiran and givosiran and we are very excited for what we believe to be the transformative potential of these investigational medicines. It should go without saying that putting three highly innovative medicines at the Phase 3 trials in any given year is a level of productivity rarely achieved in even established major global pharma companies, let alone an emerging biopharma company like Alnylam. The third area of major focus for Alnylam in 2017 is the buildup of our quality medical affairs, manufacturing and commercial teams and capabilities in North America and Western Europe in anticipation of our potential 2018 launch of patisiran and future product launches. I am going to have Barry update you on those activities at the end of this call, but rest assured that we are building an amazing team with world-class capabilities. Now before I turn the call over to Akshay to review our pipeline progress, I do want to briefly update you on the conduct of our revusiran investigation. As a reminder, revusiran was an investigational RNAi therapeutic that was in development for the treatment of patients with cardiomyopathy due to hATTR amyloidosis, a program that we discontinued in the fourth quarter of 2016 due to an imbalance in mortality events observed in the ENDEAVOR Phase 3 trial. We are on track to conclude and report the findings of this investigation this coming summer and we expect to include this report as part of our RNAi Roundtable webinar series. We will share the date for this event as well the rest of our Roundtable events in the coming weeks. When we report on results, I think you will be reassured by the thoroughness of our investigation and our transparency. We also intend to publish these findings in a peer-reviewed journal article. In the meanwhile and based on current status of this investigation, we continue to remain confident that the revusiran findings have no read through to the rest of our platform. Now with those introductory comments, I would like to now turn the call over to Akshay to review our progress in our pipeline in more detail. Akshay?
Akshay Vaishnaw: Thanks, John, and good morning everyone. As John noted, we are very focused on the advancement of our pipeline of investigational RNAi therapeutics and in particular our late stage programs. Let's begin with our programs in hATTR amyloidosis which include patisiran and ALN- TTRsc02 This is certainly a big year for patisiran with our Phase 3 APOLLO study read out later this year in September timeframe. As John commented, we believe we have good reasons to be encouraged by the prospects of patisiran based on our Phase 2 OLE study results. At the AAN meeting last week, we presented final results from the patisiran Phase 2 OLE study. At 24 months, patisiran showed a mean decrease in the modified neuropathy impairment score or mNIS+7 of seven points, providing continued evidence that patisiran has the potential to halt or improve neuropathy progression in patients with hATTR amyloidosis. This compares favorably to an expected mean 26 to 30 point increase in mNIS+7 at 24 months estimated from analyses of historical datasets in untreated hATTR amyloidosis patients with similar baseline neuropathy impairment. At this meeting, we also presented results from a new post-hoc analysis exploring the relationship between baseline neuropathy severity and changes in mNIS+7. In this analysis, patients were grouped into tertiles according to their baseline NIS scores as shown on slide nine. Patients in all three groups showed a mean improvement in mNIS+7, including patients with the greatest degree of neurologic impairment at baseline. Specifically, patisiran administration was associated with a mean 7.4 point decrease in mNIS+7 in this group with the greatest impairment at baseline. This analysis suggests that the potential clinical effects of patisiran are observed across the full range of disease severity. Moreover, in the first post-hoc exploratory analysis of its kind, patisiran administration was found to be associated with statistically significant decreases in TTR amyloid deposition as measured from blinded analysis of skin biopsy samples from the distal thigh and distal leg. This decrease in mean dermal amyloid content is consistent with the statistically significant mean increase in sweat gland observed in exploration analysis of the same skin biopsy samples over 24 months. Taken together, these exploratory analyses support the therapeutic hypothesis that reduction of mutant and wild-type TTR can potentially lead to reduction of TTR amyloid deposition and increased nerve generation. Turning to safety. Patisiran administration was found to be generally well tolerated in patients with hATTR amyloidosis out to 25 months, with no drug-related serious adverse events reported. Drug-related or possibly drug-related adverse events occur in four or more patients were flushing and infusion-related reactions, all of which were mild in severity and did not result in any discontinuations. There were ten reports of SAEs in seven patients, all of which were unrelated to study drug, including two previously reported deaths. There were no clinically significant changes in liver function tests, renal function test, hematologic parameters, including platelets. Patients who completed dosing in the Phase 2 OLE study have rolled into the global APOLLO-OLE study and we plan to report initial 36 month data from these patients in late 2017. As of today, we are pleased that more than 20 patients have now completed three years of dosing. Of course in the meanwhile, we continue dosing patients in the APOLLO Phase 3 trial. We continue to be pleased with the ongoing conduct of the study and the low discontinuation rate as we now approach our patient, last visit milestone this summer. The study remains blinded but we are certainly encouraged from an overall safety perspective by the periodic oversight of unblinded safety data by the study data monitoring committee. We are also encouraged by the very high percentage of patients who have elected to enter the APOLLO OLE study after completing 18 months of dosing in APOLLO. So by all accounts, we certainly look forward to seeing the APOLLO study results later this year. Let's now turn to fitusiran program for the treatment of hemophilia and rare bleeding disorders where we have continued to make great progress. Fitusiran is an investigational RNAi therapeutic targeting antithrombin or AT that is designed to increase thrombin generation and thus provide hemostasis in people with hemophilia. We believe that fitusiran could address the unmet needs in both hemophilia A and B with the potential to provide consistent and durable hemostatic protection for all patients and potentially a whole new treatment option for patients living with inhibitors. Moreover, as a once monthly subcutaneous injection, fitusiran has the potential to address the significant treatment burdens of current management. At a recent EAHAD meeting in Paris, we presented new results from an exploratory analysis of fitusiran Phase 1 study. In this analysis, we looked at 21 total bleed events in 41 hemophilia A and B patients treated with fitusiran, after achieving greater than 75^ antithrombin lowering was achieved. Treatment of all breakthrough bleed events with the replacement factor or bypassing agents resulting in successful hemostasis without any thromboembolic events. In addition, we presented results from stability studies of fitusiran which supported greater than two year shelf life at room temperatures storage conditions. This stability profile could potentially facilitate treatment in regions where cold chain storage requirements represents a challenge to patient access. We believe these late stage results are promising for fitusiran's potential as a treatment option for hemophilia patients with and without inhibitors. Moreover, these fitusiran results continue to highlight what we believe to be a very competitive profile for this innovative investigational medicine. We are excited to announce today that we will report additional data from the fitusiran Phase 2 OLE study in an oral presentation on July 10 at the ISTH meeting in Berlin. About 30 hemophilia A and B patients with or without inhibitors continue to receive fitusiran in the Phase 2 OLE study with the most advanced patient have received three years of treatment and with more than six treatment and with more than 15 patients at over one years of dosing. We are now transitioning fitusiran into a comprehensive Phase 3 program called ATLAS. As shown on slide 13, the ATLAS program is expected to include three separate Phase 3 trials running essentially in parallel towards the goal of obtaining broad based approval for fitusiran in hemophilia patients with or without inhibitors. We are now finalizing alignment with regulatory authorities on the pivotal study designs and expect to start ATLAS by the end of Q2 consistent with our earlier guidance. Let me now turn to recent progress with givosiran, which we are developing for the treatment of acute hepatic porphyria. Porphyrias is a group of ultra-rare orphan diseases caused by genetic defects in the heme biosynthesis pathway in the liver. These are rare devastating diseases with enormous burden. In porphyria, buildup of toxic heme intermediates lead to incapacitating and potentially fatal attacks with symptoms that include severe abdominal pain, peripheral and autonomic neuropathy and neuropsychiatric manifestations. Porphyria attacks typically last for days and require hospitalization. At the beginning of March, the FDA hosted a patient focused drug development meeting on acute porphyria, where we were able to hear from patients living with this devastating disease. Patients describe the pain during an attack as incompatible with life and the majority of patients report chronic pain even in between their attacks. Currently, the only available treatment for acute attacks is hemin, a preparation of heme derived from human blood administered via a central intravenous line. Hemin is associated with a number of complications including thrombophlebitis or coagulation abnormalities. There are no approved therapeutics for prophylactic use, although hemin is sometimes used in this manner in patients who experience recurrent attacks. Chronic administration of hemin may result in renal insufficiency, iron overload, systemic infections affecting the central venous access and, in some instances, tachyphylaxis underscoring the high unmet need in this disease. Givosiran targets the liver-expressed ALAS-1 gene which is enzyme upstream for genetic defects in the acute hepatic porphyria and the enzyme responsible for the overproduction of ALA and PBG, the toxic heme synthetic intermediates that mediate porphyria attacks. Our therapeutic hypothesis is that silencing ALAS-1 with givosiran will lower levels of ALA and PBG, thereby reducing the number, frequency and severity of porphyria attacks in patients. As a once-monthly or potentially once-quarterly subcutaneous investigational RNAi therapeutic treatment to prevent debilitating porphyria attacks, givosiran could be a transformative therapy for patients with this high unmet need disease. Recently, we were pleased that the European Medicines Agency or EMA granted givosiran a PRIME designation. The purpose of the PRIME program is to bring treatments to patients faster by harnessing the EMA support for the development of medicines for diseases where there is an unmet medical need and where early clinical data show potential to benefit patients. Through the PRIME program Alnylam will have enhanced scientific and regulatory support from the EMA, including its advice on optimization of the development pathway and the potential for accelerated assessment of the MAA. Our plan is to now complete dosing several additional cohorts of acute porphyria patients. As we announced in our press release this morning, we expect to present the next tranche of data on June 26 at the International Congress on Porphyrins and Porphyrias or ICPP meeting in Bordeaux, France. Let's now turn to inclisiran, our investigational RNAi therapeutic targeting PCSK9 that's being developed in collaboration with our partners at The Medicines Company. At the American College of Cardiology meeting in mid-March, positive final results were presented from the ORION-a Phase 2 trial of inclisiran. Specifically, as illustrated on slide 16, we reported significant and sustained reductions in LDL of over 50% that was sustained for six months supportive of a once-quarterly or biannual dosing regimen for further development. Importantly, no material safety issues were observed and the overall incidence of adverse events for inclisiran was similar to placebo. Specifically, there were no investigational drug-related elevations of liver enzymes, no neuropathy, changes in renal function, thrombocytopenia or anti-drug antibodies. The overall incidence of treatment emergent adverse events was 76% in both patients randomized to placebo and patients randomized to inclisiran, with no significant difference between inclisiran dose groups. Injection site reactions associated with inclisiran were infrequent, mild or moderate and transient. As a testament to the importance of the overall findings, these results were concurrently published in the New England Journal of Medicine. Recently, The Medicines Company announced the conclusion of its meeting with the FDA regarding the go forward clinical path for inclisiran. The FDA has confirmed that an initial approval for inclisiran could be supported by 3,000 patients randomized, double-blind, placebo-controlled study with LDL-C lowering as the primary endpoint, followed by complementary cardiovascular outcome study. This initial Phase 3 study in atherosclerotic cardiovascular disease or ASCVD patients is expected to start in mid-2017 with a read out in 2019. Finally, we also continue to evolve a number of earlier stage programs including ALN-CC5 for complement-mediated diseases, ALN-GO1 for primary hyperoxaluria and ALN-HBV for hepatitis B infection. An important milestone in this basket of programs was the initiation of patient dosing for our GO1 program where we are now looking to see if this investigational RNAi therapeutic can reduce levels of urinary oxalate that's responsible the underlying renal pathology. Basically, this is our first and the industry's first RNAi program where we are enrolling pediatric patients and we certainly aim to make a difference in the lives of young children living with this very serious condition. With that, I will now turn the call over to Mike for a review of financials. Mike?
Mike Mason: Thanks Akshay. I will be referring to slide 19 for a discussion of our first quarter 2017 financial results. We maintained a solid balance sheet ending the first quarter of 2017 with $962.2 million in cash, including restricted investments. Our GAAP revenues were $19 million in the first quarter of 2017 as compared to $7.3 million in the first quarter of 2016. Revenues for the first quarter of 2017 included $12.3 million from our alliance with Sanofi Genzyme, $6.4 million from our alliance with The Medicines Company and $0.3 million from other sources. The increase in revenues in the quarter ended March 31, 2017 as compared to the prior year period was due primarily to higher revenue from our alliance with Sanofi Genzyme. We expect net revenues from collaborators to continue to increase on a quarterly basis during the remainder of 2017 due primarily to an expected growth in revenues from Sanofi Genzyme related to increased expense reimbursement as well as the potential receipt of milestone payments under our agreements with Sanofi Genzyme and The Medicines Company. Moving to expenses. R&D expenses were $87 million in the first quarter of 2017 as compared to $96.3 million in the first quarter of 2016. The decrease in R&D expenses for the quarter ended March 31, 2017 as compared to the prior year period was due in part to a decrease in non-cash stock-based compensation expense as a result of the vesting of certain performance-based stock option awards during the first quarter of 2016 upon completion of enrollment in our APOLLO Phase 3 clinical trial for patisiran. We expect that R&D expenses will remain relatively consistent with the first quarter during the remainder of 2017 as we continue to develop our pipeline and advance our product candidates into later stage development but expect that certain expenses will be variable depending on the timing of manufacturing batches, clinical trial enrollment and results, regulatory review of our product candidates and programs and non-cash stock-based compensation expenses due to the potential vesting of performance-based awards. G&A expenses were $38.5 million in the first quarter of 2017, as compared to $21.1 million in the first quarter of 2016. The increase in G&A expenses for the quarter ended March 31, 2017 as compared to the prior year period was due primarily to an increase in headcount to support corporate growth and to prepare for the potential launch of our first commercial product. We expect that G&A expenses will increase on a quarterly basis during the remainder of 2017 as we continue to grow our operations including the anticipated buildout of our commercial infrastructure, but expect that non-cash stock-based compensation expenses will be variable due to the potential vesting of performance-based awards. The GAAP net was $107.3 million as compared to a net loss of $103 million for the same period in the previous year. With respect to guidance for 2017, we remain on track to end 2017 with greater than $700 million in cash, including $150 million in restricted investments. We believe this provides Alnylam with a very strong balance sheet at the end of 2017 to support development and commercial activities into 2018 and beyond. With that, I will now turn the call over to Barry. Barry?
Barry Greene: Thanks Mike. As you heard from John earlier, we are executing on our late stage pipeline in 2017 to achieve our Alnylam 2020 profile marking our transition from a late stage R&D company to a multiproduct commercial organization and achieving a profile rarely seen in the biopharmaceutical industry. A critical part of this transition is the expansion of our quality, medical affairs, manufacturing and commercial capabilities to support multiple planned consecutive product launches in 2018, 2019 and 2020. These efforts include building our capabilities in the United States, Canada and Western Europe for patisiran and fitusiran and then growing globally with givosiran and future products, assuming positive read outs and regulatory approvals. Let me highlight a few activities as part of this important build. First, we continue to build our quality organization in support of our overall GxP activities in preparation for preapproval inspections and of course future high quality compliance organization. Additionally, we now have an active medical affairs effort in North America and Western Europe, where our team is working on educating physicians and patient organizations on several things, including the RNAi mechanism of action, on hereditary ATTR diagnosis, on the clinical importance of thrombin generation hemophilia and other rare bleeding disorders as well as the enormous burden of disease in the acute hepatic porphyries. In our technical operations and manufacturing team, we have secured our network of contract manufacturing organizations and have completed validation of drug substance and drug product processes and batches in support of potential patisiran NDA and MAA submissions at year-end. We have also been preparing for preapproval inspections. We also continue to build out our Norton, Massachusetts drug substance facility for future drug supply. Finally, we are building out our commercial teams in North America and Western Europe with a key focus initially on patient access and on product value dossiers to secure rapid and strong reimbursement for patisiran and future products. In Western Europe, we are completing recruitment of the Country General Managers for all the major markets and we will soon announce a head of our European and Canadian business. Across our quality, medical affairs, technical operations, manufacturing and commercial activities, we are building the Alnylam for tomorrow which will fulfill our mission of bringing innovative medicines to patients in need. Importantly, you can expect Alnylam to be as innovative as a commercial stage company as we have been as an R&D company and as someone who has been involved with many successful commercial launches of products, I couldn't be more excited about what we can and will do in coming years. With that, let's now turn to slide 22 for a review over 2017 goals and guidance and upcoming data presentations. With our patisiran program, we continue dosing patients in our APOLLO Phase 3 study and look forward to reporting top line data from this study in mid-2017 with more complete data in late 2017. Assuming positive results, we expect APOLLO will enable possible NDA and MAA filings at year-end putting us in the position, assuming regulatory approval, to launch our first commercial product next year in 2018. With fitusiran, we expect to initiate the ATLAS Phase 3 program by the end of Q2 in line with our guidance. We also plan to present additional data from the Phase 2 OLE study of fitusiran at the ISTH meeting on July 10 and then again in late 2017. Now turning to givosiran. We look forward to presenting additional data from Part C of the Phase 1 trial in recurrent porphyria attack patients in mid-2017 at the ICPP meeting in late June. We plan to rapidly advance this program into a Phase 3 trial which we expect to start later this year. Regarding inclisiran, our partners at The Medicines Company are planning to initiate a Phase 3 study in patients with ASCVD in mid-2017. We also expect to advance additional programs from our early and mid-stage program and to report additional clinical data from these programs throughout the year. Finally, as Mike said, we expect to end 2017 with greater than $700 million in cash with $150 million in restricted investments, a balance sheet that will sustain us in the future. With that, I will now turn the call back to Christine to coordinate our Q&A. Christine?
Christine Lindenboom: Thank you Barry. Operator, we will now open the call for questions. Fro those dialed in, we would like to ask you to limit yourself to one question each and then get back in the queue if you have additional questions.
Operator: [Operator Instructions]. Our first question comes from Ritu Baral from Cowen and Company. Your line is open.
Ritu Baral: Good morning everyone. Thanks for taking the question. Barry, I wanted to dig in a little more on the CMC, specifically based on your slide and the comment, it looks like Alewife is going to be primarily responsible for patisiran drug supply. Can you take us through who is responsible for fill and finish? Maybe where you are on stability testing? And whether you are planning on redundant supply or just having enough inventory to address any potential issues in market supply?
John Maraganore: That's a great question, Ritu. Barry, take it away.
Barry Greene: Yes. Thanks Ritu. Several questions there. So let me start with patisiran and just say this, we have secured the supply chain of the raw materials, drug substance and drug product as well as fill and finish. Across that supply chain, there are multiple redundant sites, Specifically for drug substance, we have, as we mentioned, fulfilled our validation batches with a third-party manufacturer and we will be building inventory as a strategy for launch readiness. As you mentioned Alewife here in Cambridge will be our local drug product supply and again our strategy is to build inventory for launch. And then we have multiple fill and finish sites online for both U.S. and Europe. So we feel pretty good about the about patisiran. The initial strategy will mainly be security build and then over the course of launch, we will have redundant systems set up as well.
Ritu Baral: Got it.
John Maraganore: There was also a question on stability, Barry. You want to take that.
Barry Greene: Sorry about that. Yes, stability. So in patisiran, we run multiple stability lots and we have stability out over two years that will require a cold chain storage delivery.
Ritu Baral: Got it. And you mentioned inspections. Can you tell us which of the facilities still need inspections or which of them are GMP certified at this point?
Barry Greene: Yes. So the CMOs we are working with have had preapproval inspections for other products. As you are probably aware, as we get closer to a positive APOLLO and filing, that's when the preapproval inspections mainly happen. And really, it's up to the agencies for where along the supply chain they want to inspect, both on CMOs and our sites as well. But we are prepared across the sites and across the supply chain for those inspections.
Ritu Baral: Great. Thanks for taking all the questions.
John Maraganore: Great. Thanks Ritu.
Operator: And our next question comes from Alan Carr from Needham & Company. Your line is open.
Alan Carr: Hi. Thanks for taking my questions. I wonder if you could talk about the TTR program here. If the patisiran trial reads out positive, where does TTRsc02 stand? And how quick you think you can move that forward with patisiran? And then the other question is, with respect to your commercial build, what's your thoughts on timing for sales force and that sort for thing? Thanks.
John Maraganore: Terrific. Well, we will have Akshay answer the first question and Barry, the second. So Akshay.
Akshay Vaishnaw: Yes. Hi Alan. So with respect to the TTRsc02, as you know we have presented very exciting Phase 1 data showing greater than 89% knockdown with durability after six months from a single injection and we are excited to move that forward as soon as APOLLO reads out. I think that leads to rapid engagement with the regulatory agencies and depending on the exact nature of the data from APOLLO, I think we can negotiate variety of approaches to seeking approval for TTRsc02. So provided the data is robust and the primary endpoints met and we can show relationships in TTR knockdown and the clinical outcomes, I think we can have a conversation about further developing TTRsc02 on approval based on TTR knockdown and safety. We could also have conversations about single arm studies and comparative historical controls. It would be difficult to do a comparative study at that point. So there are a number of approaches we are working through and certainly the details of how APOLLO reads out and the content of that data will be very important to discussion.
John Maraganore: All right. Barry, on the commercial question?
Barry Greene: Yes. So as we talked about on the call, we have been steadily building out all the capability required to go-to-market including medical affairs and commercial. So we have got medical affairs folks deployed in U.S. and in Europe to help the education of hereditary ATTR amyloidosis and really initiate the patient finding activities. As I mentioned on the call, we are targeting general managers in the major markets in Europe and that's a little bit different for patisiran than it might be for other products because of the uniqueness of where patients are found, for example, Spain, Portugal, so the Iberia, Sweden as well as Germany, U.K., France. And those general managers are in place and as I mentioned on the call, will be heading, will be highlighting the head of our European Canadian organization as well. Post-APOLLO, we will be building out other countries throughout Western Europe and Canada and the United States again we are well on our way for patient finding, diagnosis and access as well. We think that the timing works well for post-APOLLO to really then be bringing on the in-field force account management sites and we are preparing to do that post a positive APOLLO.
Alan Carr: What's the scale of the sales force that you are thinking of in the U.S.?
Barry Greene: Well, you can imagine, for competitive reasons, we are not giving detailed information on all of our field deployed folks, but for U.S. and Western Europe and Canada, less than 100 people required in the field across all the countries I mentioned and the U.S. have an effective launch and subsequent commercialization of patisiran. So it really is a very focused effort, as you often see with orphaned and rare diseases.
Alan Carr: Great. Thanks very much.
John Maraganore: All right. Thank you Alan.
Operator: And our next question comes from Do Kim from BMO. Your line is open.
Do Kim: Hi. Good morning. Thank you for taking my questions.
John Maraganore: Good morning.
Do Kim: Hello.
John Maraganore: Yes. Good morning.
Do Kim: Hi. For patisiran, I thought the Phase 2 final data continued to look strong, but how should we think about the secondary endpoints that didn't move toward improvement, like mBMI or intra-epidermal nerve-fiber density. And is there a natural history that would compare that to?
John Maraganore: Yes. That's a great question. I will just comment and then Akshay can take it over. Keep in mind that the study is not comparative to placebo and so what we appear to see at some of those endpoints is stability over two year period which is itself quite encouraging, based on the natural history. But Akshay, do you want to give some further color on that?
Akshay Vaishnaw: Yes. I think you said the main thing that we don't have a comparator arm and I think there aren't very good historical data sets around mBMI and this spectrum of, the last one or stage one or stage two patients that we have in the face of label extension study. But I think given the totality of the data set where we have seen changes, reductions in over 70% of patients in mNIS +7, improvements in nerve density and now a very, I think, rather interesting and impressive reductions in amyloid burden. If we add a comparator arm, I would be optimistic that patisiran changes in mBMI would be superior to placebo. So we will have to wait for APOLLO. I think the retention of 25 patients in the study for almost three year is really [indiscernible] speaks to, by inference to have this drug as likely performing from a safety and efficacy viewpoint in this single arm study. So that makes us feel optimistic about that endpoint. Vis-Ã -vis the density work, I think we got to be very cautious. The very fact, number one, that we are seeing increases in nerve density in an inherited neuropathy that's inexorably progressive is absolutely remarkable and this is something that all the KOLs remarked upon. Now with the specifics of where the curves are at different time points, remember the biopsies are taken randomly from different parts of the leg at the sequential time points. And so the amount of nerve, how can I put this, the change in amyloid burden on the nerves and the exact dimension is varied along the length of the nerve in the legs and the alms. So depending on where exactly the biopsy is taken at the sequential time points will profoundly will alter the result. So if at one-time point happened to get a patch of nerve that was very damaged, you will see more damage if at another time point you see an area that's less damaged, you will see less evidence of nerve density loss. You got to have average the whole thing out. You have got to look at the whole population. And that's where the result, I think, looks impressive. So the fact that one or two patients may skew a particular time point is probably not relevant.
John Maraganore: It's just worth adding on this point that these biopsy samples are all read in a masked manner by a central lab metal and a lab that is world-renowned for this type of analysis. So it is something which is reassuring that we are seeing these type of effects in a blinded fashion with an objective what really is an objective measure of clinical activity for the drug.
Akshay Vaishnaw: As is the other relationships that we have shown before, the degree of knock down of transthyretinis is related to changes in mNIS +7. That's also very objective. So I think all these factors together suggest that something important happening in this study.
Do Kim: Great. Thank you. That was very helpful.
John Maraganore: Yes. Thank you.
Operator: And our next question comes from Geoff Meacham from Barclays. Your line is open.
Evan Seigerman: Hi guys. This is Evan, on for Geoff. Thanks for taking the question. One on fitusiran. When we think about where this fits in with all the novel agents in development, where do you see this study with gene therapy long acting factor? How should we be thinking about the competitive landscape with these novel assets coming forth?
John Maraganore: Yes. Let me take a start and then maybe Akshay or Yvonne or Barry might want to comment. This is an exciting time for hemophilia. This is an era where patients really suffering with this disease are going to see a level of innovation that they have not seen for decades, really since the advent of recombinant DNA technology nearly 20 or 30 years ago, 30 years ago. Nothing has really come forward that is close to the level of innovation that one sees these days for people living with hemophilia. So it's a very, very exciting time. There is a buzz in the patient communities when we go to meetings and also in the in the scientific conferences and so forth. Very exciting time. Now when we think about the landscape of medicines that are emerging right now, when we think about the subcu drugs, which is emicizumab or ACE-910 and patisiran. And when we think about the gene therapy products for heme A and for heme B, there is no doubt that all of these approaches show promise, that all of these approaches have the potential to together disrupt the age-old use of factor, the way it's been used in the old days and that, from the standpoint of a market disruption and new innovation, is a real opportunity, in our view, for all of these medicines to do very well in, what is today, a $10 billion market. So it's our view that obviously depending on final clinical trial results, that patisiran is going to fit in very nicely into this landscape of emerging changing dynamic market and it's going to be a product that is really differentiated. It's obviously a subcu drug given once a month that is going to be effective, we believe in heme A and heme B. Of course, there is nothing in heme B like patisiran, because emicizumab or ACE-910 is limited to patients with heme A and of course both emicizumab and patisiran are going to very meaningful for patients with inhibitors and of course that's not a realm where gene therapy type products will emerge. I am of the view that gene therapy is going to be important in this space. I don't think it's going to have a very rapid uptake. There is going to be a number of barriers to entry that relate to long-term safety and variability of response. But the data are in fact promising and I think that gene therapy will emerge as one of the treatment options out there. So that's a long-winded answer to your question and let me see if any of my colleagues have anything else to add to it that I haven't quite covered. And they are shaking their heads saying, no. But does that answer your question, Evan?
Evan Seigerman: That does most definitely. And then one, when we get the potential Ionis data, what are some of the things that we need to watch out for so we don't have that misreading of the data and inaccurate extrapolation into the APOLLO trial?
John Maraganore: Well, Evan, it's going to depend a little bit on how much clarity is in what Ionis shares and it's sort of hard for me to prejudge what that is or is not going to be. But look, we do expect it to be positive. We do expect them to have sufficient power with all the limitations that we discussed to still eek out a positive study. But there, if it's borderline, like p=0.55 or something, that could reflect the fact that they are underpowered and had a shorter timeline or a time frame for their primary endpoint than we did. And so I think we are all going to have to see what's disclosed by Ionis and then obviously interpret that as we will all interpret it. But we do expect it to be positive. We do know that have had a lot of adverse event issues and that's going to factor into their efficacy results that they a lot of discontinuations. And so how transparent they will be on that in their top line release, we don't know at this point in time. We can only speculate on that. Anything else to add from the team?
Evan Seigerman: Thank you very much. I appreciate it.
John Maraganore: Great, Evan.
Operator: And our next question comes from Alethia Young from Credit Suisse. Your line is open.
Alethia Young: Hi guys. Thanks for taking my question. A couple, sort of tied in together. One, just in your conversations with the FDA like, is a trend enough on the Norfolk score? I know it's one of Ionis' primary endpoints. So I just wanted to reconcile the two points there. And then also when you are thinking about filing these two in the U.S. versus the EU, if this was obviously approved in Europe and not the U.S., but are there different dynamics and in thinking about regulatory filings there? Thanks.
John Maraganore: Yes. Akshay, do you want to comment? I will just start by saying we don't want to get into the details of our regulatory discussions for competitive reasons at this point. But Akshay, you want to comment?
Akshay Vaishnaw: Yes. I think overall, Alethia, when it comes to working with the FDA and any regulatory, in general, the key principle is as long as there is internal consistency within the data set, I think we can have important dialogue of how to get a medicine approved for these high unmet need patients. So the specifics of what the Norfolk may or may not be and the trends, there is no point in discussing that. We have to look at hitting the primary and the overall internal consistency of the data set and does it point to drug having done something important with an adequate safety profile in this patient population. And that really is how the agency thinks about it. With respect to the EMA, those principles are equally important there. And so we look forward to working with them within the protocol that was partly discussed with both agency prior to initiation of Phase 3. So we feel we are aligned in our approach. And we will find out in September.
John Maraganore: Yes. I would just add, Alethia, that you can imagine that if our study shows a very large treatment effect and is very robust, the quality of life measure is important and obviously, one would like to hit it and we believe that we will hit it. But if the importance of it is different then in a study outcome which is more muted, maybe more or less of a treatment effect, less robust P value, then the agency and ultimately payors looking for what's the clinical impact to that becomes much more important. So that's another way to look at it in part. Barry, do you have a comment?
Barry Greene: Yes. You also asked about U.S. and Europe. The only that I would add is that even though tafamidis is in the market in most countries in Europe, but the agencies and the countries themselves that we had been meeting with for scientific recognized the unmet need that remain is very, very high.
Alethia Young: Great. Thanks.
John Maraganore: Yes. Thanks Alethia.
Operator: And our next question comes from Ted Tenthoff from Piper Jaffray. Your line is open.
Ted Tenthoff: Great. Happy Friday everyone.
John Maraganore: Happy Cinco de Mayo.
Ted Tenthoff: Cinco de Mayo, exactly. So a comment, if I may, first and then a question. And just listening to comments and it really took me back all the way to the IPO and your guys appreciation for the sheer scale that was going to be required to take a new class of medicines to patients. I am pleased to see all that progress and the continued commitment to doing this the right way as you build up the commercial organization and seek the first regulatory approval. My question is on givosiran and I was really impressed by the preliminary data. I think this is pretty unique opportunity for Alnylam. What's still really has to be done before we start the Phase 3 here? It's really just finalizing that dose, optimizing that dose? Do you feel pretty comfortable with the endpoints?
John Maraganore: Yes. Akshay, do want to comment?
Akshay Vaishnaw: Yes. Thanks Ted. With givosiran, as you said, the preliminary data, indeed very encouraging and the PRIME designation attest to that. The key thing to wrap up now is to share the data from this Phase 1 study with the agencies and finalize the trial design. We feel that we have got through the literature, through working with KOLs around natural history, study and discovery and what we have learned from the Phase 1 study itself, we have got a very good handle on the primary endpoint revolving around the attack frequency. These attacks were clinically devastating and therefore meaningful. So no one would, I think, debate importance of attacks. And know, we are in the process of working with regulators and we feel we are on track to start what will be hopefully a very straightforward, placebo-controlled study comparing patients with givosiran to placebo and determine attack frequency. The current trial, I think, has given us great insights into the dosing frequency that we will need to maintain optimal suppression of attacks and at the ICPP towards the end of June, we will share all of those data with you.
Ted Tenthoff: Great. And I guess a quick follow-up to that. How important is patient selection going to be in that Phase 3 study? Is the magnitude greater and it should play out versus placebo. But how are you thinking about patient enrollment criteria?
John Maraganore: Yes. It's a great question.
Barry Greene: Yes. Enlistment, of course, was very important when you are listing a signal that you want to address with an important drug like this. So we are going to reach for patients with recurrent attack and we are thinking about patients with multiple attacks, approximately something like four or more attacks per annum. We do want to finalize that with the regulators. I don't think there should be a big debate around that. But that's the obvious area to focus on and it's the highest unmet segment.
John Maraganore: Does that answer your question?
Ted Tenthoff: It sure does. Thanks guys.
John Maraganore: Great. Thanks Ted.
Operator: And our next question comes from Christopher James from Ladenburg Thalmann. Your line is open.
Christopher James: Hi. Good morning guys and thanks for taking my question. I just have one question regarding the histology data at AAN last week. You might have touched upon this earlier. But can you comment on, how did the skin biopsy data, namely the reduction in amyloid compare with the increases in nerve density data and changes in mNIS+7? Can you comment on at least directionally or magnitude of change? And will you be including any of this in your filing?
John Maraganore: Yes. Great question.
Barry Greene: Yes. So Chris, the latter part of your question first. We have similar types of data on nerve density and amyloid content. That will be submitted with APOLLO. We obviously don't have those data yet. That's all in process. But I think that will be a very important part of the data set. And so that's one thing. With respect to relationships between nerve density or neuroid density and the amyloid change, again that's something we were discussing earlier. Imagine a nerve traveling the length of the leg from the thigh down into the lower leg, there will be patchy deposition of amyloid all along the length of that nerve and nerve density will vary along the length of that nerve. It will be lowest distally and it will be greater proximally. Now when you do biopsies over time, you are not sampling exactly the same area over and over again. So variations can easily result within a patient. And I think the important thing is to look at the overall result. And the one we are seeing, as we discussed, I think is very important and the types of the setting, I mean it never has really been shown in any other inherited neuropathy, to my knowledge. And so we are very excited by these findings. With a larger data set like APOLLO, where hundreds of patients were involved, I think the kinds of correlations you are talking about will be much easier to analyze at the group level.
John Maraganore: And I will just, Chris, that we are really impressed with the number of patients in APOLLO who have agreed to do the biopsy. It's not a mandatory requirement as it typically isn't in a protocol. But we have pretty significant numbers of biopsy samples, actually. So that will be a meaningful part of our APOLLO review and certainly our submission to the FDA and EMA.
Christopher James: Great. Thank you for taking the question.
Operator: And our next question comes from Paul Matteis from Leerink. Your line is open.
Paul Matteis: Great. Thanks so much guys and congrats on all the progress. Two quick questions. One on quality of life. I am wondering, do you think 15 months or 18 months are long enough to show benefit in quality of life for the TTR knockdown therapies? And then second, thanks for sharing some thoughts on the revusiran analysis. Do you think that this kind of analysis is going to be important for FDA as part of the patisiran regulatory review, given that it's the first RNAi therapeutic that would be reviewed for potential approval? Thanks so much.
John Maraganore: Great. Those are great questions. Akshay, do you want to handle it?
Akshay Vaishnaw: Yes. So with respect to the patisiran QOL question, what we know is there are very good relationships between change in NIS and change in these QOL parameters. We have shared those data previously. And that's really very, very encouraging. And I think the kinds of changes in NIS that we are seeing in the context of this Phase 2 open label extension study, if we have changes of that type or greater, we can be optimistic that there should be notable changes in the Norfolk score in the APOLLO study. So certainly, with a sample size of 225 followed after 18 months and changes of this magnitude based upon the TTR knockdown that we have, we feel like we are in a good place and we are optimistic. Now if you have a smaller file size, if your TTR knockdown knowledge is great, if there has been great discontinuation rate from the study, we don't know. And so hard to speak to other circumstances. But certainly in our context, I think, we are feeling optimistic. With respect to your question on revusiran, I think first and foremost, the agency literally uses this phrase with all forms when drugs are being discussed. It's a case-by-case basis. So in the first setting, patisiran will be evaluated in and of itself. And that will be first line of practice. Now within that context, certainly cardiac safety will be borne in mind also by them and I think what we see in terms of cardiac safety with respect to the Phase 2 open label extension study looks quite encouraging. If you look at the overall study, the cardiac parameters have been stable. We haven't had any cardiac morbidity and mortality of note. And so we think as the cardiac issue is examined, we hope that APOLLO too will provide favorable outlook as the Phase 2 study is done. Ultimately, it will be a matter of review and if they have questions about revusiran, we are happy to share data our data as we have been doing, as the investigation has been ongoing. And we are going to bring all the data out in the summer anyway, as John commented earlier. So that's how we think about it currently.
John Maraganore: And I will just add that we have had good discussions with the FDA already on the revusiran investigation and we will update them yet further. So they are aware and I think pleased with the thoroughness and the type of work that we are doing on that matter. And so that's something which we will certainly engage with them before we go publicly, but we have already had engagement with them on that in a very thorough and definitive manner.
Paul Matteis: Okay. Great. Thank you so much.
John Maraganore: Thank you Paul.
Operator: And our last question comes from Madhu Kumar from Chardan. Your line is open.
Madhu Kumar: Hi. Thanks for taking my questions. First one is, thinking about the hemophilia space, particularly ACE-910 from Roche and the data we are going to be getting at ISTH on the HAVEN 1 trial, what do you understand to be an unacceptable safety profile for a hemophilia drug in the inhibitor population? And then thinking about the Phase 3 studies in TTR polyneuropathy of yours and Ionis', what do you guts think is a reasonable discontinuation rate? Is it what's been seen in the Phase 2 open label extension for patisiran or something greater considering the presence of a placebo arm?
John Maraganore: Those are two great questions. Let me do the first one of them and then maybe Akshay, you take the second. In terms of the emicizumab data that will be presented at ISTH, we all look forward to seeing it. Roche's top line that it is a positive study and that doesn't surprise any of us. Of course, there have been five thromboembolic events of note to-date, one which was sadly fatal and obviously we will get more color, I am sure, on those events and the overall safety profile as well as the effectiveness profile of emicizumab at ISTH. So I think it will be premature for us to comment on what's a minimal profile. Obviously it needs to have a competitive hemostatic profile of reducing ABR. I think that we can expect that to be the case. And of course the safety profile beyond these five known thromboembolic events, you should continue to look, these look good because certainly in the non-inhibitor population that's going to be an important factor. Obviously, in the inhibitor population, there is a very high unmet need and even the current profile that's emerging for emicizumab is likely to be used at least in some patients. So I think their uptake of that product is going to be partly influenced by what's happened to date and let's see if that holds just with those five events. So we will have to see, it might be a little bit too premature to speculate I think at this point. And then the second question, Akshay, on the fitusiran?
Akshay Vaishnaw: On the fitusiran, sorry, the discontinuation rate, that's right. We have excellent retention, as you commented, in the Phase 2 open label extension study. I can say that retention in the Phase 3 study has also been excellent without getting to the specifics of the numbers. And we were powered to drop our rate well in excess of what has been seen and given that the study is approaching its last patient, last visit, I think we feel very good about maintaining adequate power per the original hypothesis when the study was designed. So I think that's as much as I can say as far as any competitor trial, you will have to speak to them. But I think we are going to be in good shape from that perspective.
John Maraganore: I will just add, Madhu, that we have also been pleased with the very high number of patients that have transitioned from APOLLO in to the APOLLO open label study, which is also a good sign of retention and patient interest to stay on top in the therapy. And as you may know, we have recently opened up an expanded access program to make patisiran available and there is very strong interest in that program by patients that were tabled to enter into the clinical studies and that just highlights the unmet need and also the favorable experience we have had to-date with patisiran from a safety perspective and also based on the Phase 2 open label data from an efficacy perspective as well. So that's encouraging.
Madhu Kumar: All right. Thanks very much guys. Have a great weekend.
John Maraganore: Yes. You too, Madhu.
Operator: And at this time, I am showing no further questions.
John Maraganore: Great. Well, thank you everyone for joining us this morning. As I said at the beginning, 2017 is a pivotal year for Alnylam's transition toward a commercial stage company, which is very exciting and we look forward to updating you on our progress in the months to come. Thank you.
Operator: Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program. You may now disconnect. Everyone have a great weekend."
